Back to Dashboard










Becton, Dickinson and Company (BDX)
Real-time intraday values
Market Overview
From:
To:
BDX Intraday
No data available
SymbolBDX
IPO DateFeb 21, 1973
CEOMr. Thomas E. Polen Jr.
Full Time Employees72k
SectorHealthcare
IndustryMedical Instruments & Supplies
CountryUnited States
ExchangeNYSE
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.77% | -1.54 US$ |
| 5 Days | +3.72% | +7.13 US$ |
| 1 Month | +8.96% | +16.36 US$ |
| 6 Months | +30.72% | +46.74 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of BDX...
Key Statistics
Market Cap
54.18B
P/E Ratio
46.26
Div Yield
2.11%
52W High
$200.47
52W Low
$127.59
Analyst Consensus
ConsensusBuy
Bullish850.0%
Neutral743.8%
Bearish16.3%
52W Analyst Price Targets
Min Target
$165.00
$165.00
Max Target
$225.00
$225.00
Current$198.88
Avg Target$195.57
Analyst Recommendations
Target Price:$195.57($165.00 - $225.00)
Community Thoughts
Share your analysis and sentiment on BDX
Join the community to share your analysis
Latest News for BDX

What Becton Dickinson Stock's New U.S. Manufacturing Deal Means For Shareholders
Simply Wall St.•Oct 23, 2026, 04:07 PM

Becton Dickinson (BDX) Stock Trades Below Fair Value After A 40% Run
Simply Wall St.•Oct 23, 2026, 03:18 PM

ResMed Set to Report Q1 Earnings: What's in the Cards for the Stock?
Zacks•Oct 23, 2026, 11:55 AM

Is Becton Dickinson (BDX) Fully Priced As Execution Improves Before Earnings?
Simply Wall St.•Oct 23, 2026, 06:08 AM

BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
Zacks•Oct 22, 2026, 05:21 PM

Can Boston Scientific Stock Jump 30%?
Trefis•Oct 22, 2026, 11:45 AM

ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
Zacks•Oct 22, 2026, 11:45 AM

Can Boston Scientific Stock Bounce Off This Support Again?
Trefis•Oct 22, 2026, 01:29 AM

DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Zacks•Oct 21, 2026, 01:45 PM

BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance?
Zacks•Oct 21, 2026, 12:26 PM